TAR DNA-binding protein 43 accumulation in protein aggregate myopathies

Journal of Neuropathology and Experimental Neurology

Volumn 68, Issue 3, 2009, Pages 262-273

  Olivé, Montse ^a   Janué, Anna ^a   Moreno, Dolores ^a   Gámez, Josep ^b   Torrejón Escribano, Benjamín ^c   Ferrer, Isidre ^a,d  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Desminopathy; Inclusion body myositis with Paget disease of bone and frontotemporal dementia; Myotilinopathy; Sporadic inclusion body myositis; TDP 43; Valosin

Indexed keywords

MICRORNA; TAR DNA BINDING PROTEIN; UBIQUITIN; VALOSIN CONTAINING PROTEIN; CYTOSKELETON PROTEIN; DNA BINDING PROTEIN; MUSCLE PROTEIN; MYOT PROTEIN, HUMAN; PEPTIDE; PROTEIN TDP-43; VALOSIN;

ADULT; AGED; ARTICLE; CASE REPORT; CELL NUCLEUS; CYTOPLASM; DEGENERATIVE DISEASE; DESMINOPATHY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; HUMAN TISSUE; INCLUSION BODY MYOSITIS; MALE; MUSCLE BIOPSY; MYOTILINOPATHY; PAGET BONE DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATE MYOPATHY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; UBIQUITINATION; CONFOCAL MICROSCOPY; DEMENTIA; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CYTOSKELETAL PROTEINS; DEMENTIA; DNA-BINDING PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; HUMANS; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; MUSCLE PROTEINS; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; PEPTIDES; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UBIQUITIN;

EID: 65349175153     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181996d8f     Document Type: Article

References (68)

1. Sherman MY, Goldberg Al. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative disease. Neuron 2001; 29:15-32
2. Ellis RJ, Pinheiro TJT. Danger-misfolded proteins. Nature 2002;416: 483-484
3. Carrell RW, Lomas DA. Conformational disease. Lancet 1997;350: 134-138
4. de Pril R, Fischer DF, van Leeuwen FW. Conformational diseases: An umbrella for various neurological disorders with an impaired ubiquitin-proteasome system. Neurobiol Aging 2006;27:515-523.
5. Goebel HH, Muller HD. Protein aggregate myopathies. Semin Pediatr Neurol 2006;13:96-103
6. Goebel HH, Fardeau M, Olive M, et al. 156th ENMC International Workshop: Desmin and protein aggregate myopathies, 9-11 November 2007, Naarden, The Netherlands. Neuromuscul Disord 2008;18: 583-592
7. Nakano S, Engel AG, Waclawik AJ, et al. Myofibrillar myopathy with abnormal foci of desmin positivity. I. Light and electron microscopy analysis of 10 cases. J Neuropathol Exp Neurol 1996; 55:549-562
8. De Bleecker JL, Engel AG, Ertl B. Myofibrillar myopathy with foci of desmin positivity. II. Immunocytochemical analysis reveals accumulation of multiple other proteins. J Neuropathol Exp Neurol 1996;55: 563-577
9. Selcen D, Ohno K, Engel AG. Myofibrillar myopathy: Clinical, morphological and genetic studies in 63 patients. Brain 2004;127: 439-451
10. Ferrer I, Olivé M. Molecular pathology of myofibrillar myopathies. Expert Rev Mol Med 2008;10:25
11. Selcen D, Engel AG. Mutations in myotilin cause myofibrillar myopathy. Neurology 2004;62:1363-1371
12. Olive M, Goldfarb LG, Shatunov A, et al. Myotilinopathy: Refining the clinical and myopathological phenotype. Brain 2005;128:2315-2326
13. Goldfarb LG, Park KY, Cervenakova L, et al. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet 1998;19:402-403
14. Muñoz-Mármol AM, Strasser G, Isamat M, et al. A dysfunctional desmin mutation in a patient with severe generalised myopathy. Proc Natl Acad Sci U S A 1998;95:11312-11317
15. Barrachina M, Moreno J, Juves S, et al. Abnormal up-regulation of neuron-restrictive silencer factor target genes in human myotilinopathy. Am J Pathol 2007;171:1312-1323
16. Askanas V, Engel WK. Inclusion-body myositis: A myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006;66:S39-48.
17. Dalakas MC. Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006;2:437-447
18. Ou SH, Wu F, Harrich D, et al. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 1995;69:3584-3596
19. Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 2001;276:36337-36343
20. Buratti E, Brindisi A, Giombi M, et al. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: An important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem 2005;280:37572-37584
21. Buratti E, Baralle FE. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci 2008;13: 867-878
22. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-133
23. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem de Munain, Biophys Res Commun 2006;351:602-611
24. Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007;61:427-434
25. Neumann M, Kwong LK, Sampathu DM, et al. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: Protein misfolding diseases without amyloidosis. Arch Neurol 2007;64: 1388-1394
26. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442:920-924 (Pubitemid 44285947)
27. .27. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442:916-919 (Pubitemid 44285946)
28. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004;36: 377-381
29. Watts GD, Thomasova D, Ramdeen SK, et al. Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet 2007;72:420-426
30. Kimonis VE, Mehta SG, Fulchiero EC, et al. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotem-poral dementia. Am J Med Genet 2008;146A:745-757
31. Hübbers CU, Clemen CS, Kesper K, et al. Pathological consequences of VCP mutations on human striated muscle. Brain 2007;130:381-393
32. Neumann M, Mackenzie IR, Cairns NJ, et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol 2007;66:152-157
33. Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiat 2008;79:1186-1189
34. Olivé M, Armstrong J, Miralles F, et al. Phenotypic patterns of desminopathy associated with three novel mutations in the desmin gene. Neuromusc Disord 2007;17:443-450
35. Olivé M, van Leeuwen FW, Janué A, et al. Expression of mutant ubiquitin (UBB+1) and p62 in myotilinopathies and desminopathies. Neuropathol Appl Neurobiol 2008;34:76-87
36. Sanelli T, Xiao S, Horne P, et al. Evidence that TDP-43 is not the major ubiquitinated target within the pathological inclusions of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2007;66:1147-1153
37. Dickson DW, Josephs KA, Amador-Ortiz C. TDP-43 in differential diagnosis of motor neuron disorders. Acta Neuropathol 2007;114:71-79
38. Fujita Y, Mizuno Y, Takamata M, Okamoto K. Anterior horn cells with abnormal TDP-43 immunoreactivities show fragmentation of the Golgi apparatus in ALS. J Neurol Sci 2008;269:30-34
39. Nishihara Y, Tan CF, Onodera O, et al. Sporadic amyotrophic lateral sclerosis: Two pathological patterns shown by analysis of distribution of TDP-43-immunoreactive neuronal and glial cytoplasmic inclusions. Acta Neuropathol 2008;116;169-182
40. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319:1668-1672
41. Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008;40:572-574
42. Gitcho MA, Baloh RH, Chakraverty S, et al. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol 2008;63:435-438
43. Kwong LK, Uryu K, Trojanowski JQ, et al. TDP-43 proteinopathies: Neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals 2008;16:41-51
44. Uryu K, Nakashima-Yasuda H, Forman MS, et al. Concomitant TARYDNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 2008;67:555-564
45. Geser F, Wintion MJ, Kwong LK, et al. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 2008;67:33-45
46. Higashi S, Iseki E, Yamamoto R, et al. Concurrence of TDP-43, tau and synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res 2007;1184:284-294
47. Freeman SH, Spires-Jones T, Hyman BT, et al. TAR-DNA binding protein 43 in Pick disease. J Neuropathol Exp Neurol 2007;67:62-67
48. Lee EB, Lee VM, Trojanowski JQ, et al. TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. Acta Neuropathol. 2008;115:305-311
49. Ferrer I, Mártýn B, Castaño JG, et al. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropath Exp Neurol 2004;63:484-498
50. Ferrer I, Carmona M, Blanco R, et al. Involvement of clusterin and the aggresome in abnormal protein deposits in myofibrillar myopathies and inclusion body myositis. Brain Pathol 2005;15:101-108
51. Janué A, Odena MA, Oliveira E, et al. Desmin is oxidized and nitrated in affected muscles in myotilinopathies and desminopathies. J Neuropath Exp Neurol 2007;66:711-723
52. Janue A, Olivé M, Ferrer I. Oxidative stress in desminopathies and myotilinopathies: A link between oxidative damage and abnormal protein aggregation. Brain Pathol 2007;17:377-388
53. Winton MJ, Igaz LM, Wong MM, et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem 2008;283:13302-13309
54. Hasegawa M, Arai T, Nonaka T, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008;64:60-70
55. Inukai Y, Nonaka T, Yoshida M, et al. Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett 2008;582: 2899-2904
56. Strong MJ, Volkening K, Hammond R, et al. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci 2007;35:320-327 (Pubitemid 46843567)
57. Ge WW, Leystra-Lantz C, Wen W, Strong MJ. Selective loss of rans-acting instability determinants of neurofilament mRNA in amyotrophic lateral sclerosis spinal cord. J Biol Chem 2003;278: 26558-26563
58. Gregory RI, Yan KP, Amuthan G, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004;432:235-240
59. Shivdasani RA. MicroRNAs: Regulators of gene expression and cell differentiation. Blood 2006;108:3636-3653
60. Nelson PT, Keller JN. RNA in brain disease: No longer just Bthe messenger in the middle. J Neuropathol Exp Neurol 2007;66:461-468
61. Thum T, Cataluci D, Bauersachs J. MicroRNAs: Novel regulators in cardiac development and disease. Cardiovasc Res 2008;79: 562-570
62. McCarthy JJ, Esser KA. MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol 2007; 102:306-313
63. Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007;129: 303-317
64. McCarthy JJ, Esser KA, Andrade FH. MicroRNA-206 is overexpressed in the diaphragm but not the hindlimb muscle of mdx mouse. Am J disease and dementia with Physiol Cell Physiol 2007;293:C451-457
65. Callis TE, Deng Z, Chen JF, Wang DZ. Muscling through the microRNA world. Exp Biol Med 2008;233:131-138
66. van Rooij E, Liu N, Olson EN. MicroRNAs flex their muscles. Trends Genet 2008;24:159-166
67. McCarthy JJ. MicroRNA-206: The skeletal muscle-specific myomir. Biochem Biophys Acta 2008;1779:682-691
68. Sweetman D, Goljanek K, Rathjen T, et al. Specific requirements of MRFs for the expression of muscle specific microRNAs, mir-1, miur-206 and miR-133. Dev Biol 2008;321:491-499